HER2-negative

About

Biomarker type: Protein expression

Marker: Human epidermal growth factor receptor 2 (HER2)

Unit: status

Equality: =

Value: Negative

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Tamoxifen
EMA (2) FDA (4) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (4) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (4) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Anastrozole
EMA (2) FDA (4) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (4) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (2) FDA (4) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
EMA (1) FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
EMA (1) FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Fulvestrant
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) FDA (2) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (2) AKT1 oncogenic variants, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) AKT1 oncogenic variants, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) AKT1 oncogenic variants, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (2) AKT1 amplification, ER positive, HER2-negative Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) AKT1 amplification, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) AKT1 amplification, ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive, PTEN nonsense variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive, PTEN frameshift variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive, PTEN splice site variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (2) ER positive, HER2-negative, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive, PTEN deletion Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (2) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Elacestrant
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Everolimus, Exemestane
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant
EMA (1) FDA (4) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (4) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (1) FDA (4) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Ribociclib
EMA (2) FDA (4) ER positive, HER2-negative Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (4) HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (4) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Fulvestrant, Palbociclib
EMA (2) FDA (4) HSE (1) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (2) FDA (4) HSE (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Olaparib
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (2) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
FDA (2) HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab
EMA (1) FDA (2) HSE (4) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Carboplatin, Cyclophosphamide, Doxorubicin, Paclitaxel, Pembrolizumab
EMA (1) FDA (2) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Paclitaxel, Pembrolizumab
EMA (1) FDA (2) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Carboplatin, Gemcitabine, Pembrolizumab
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Ribociclib
EMA (1) FDA (2) HSE (2) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (2) HSE (2) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (1) FDA (2) HSE (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
EMA (2) FDA (2) HSE (1) ER negative, HER2-negative, PR negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Sacituzumab govitecan
EMA (1) FDA (2) HSE (1) BRCA1 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
EMA (1) FDA (2) HSE (1) BRCA2 pathogenic variants, HER2-negative Invasive Breast Carcinoma Talazoparib
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Anastrozole, Goserelin, Ribociclib
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
EMA (1) FDA (4) ER positive, HER2-negative, PIK3CA oncogenic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (4) HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (4) ER positive, HER2-negative, PIK3CA oncogenic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (2) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Zolbetuximab
EMA (1) FDA (2) CLDN18.2 >= 75%, HER2-negative Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Zolbetuximab
EMA (1) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Nab-paclitaxel, Pembrolizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
EMA (1) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Carboplatin, Fluorouracil, Pembrolizumab
EMA (1) HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Esophageal Adenocarcinoma Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Nivolumab, Oxaliplatin
EMA (1) HSE (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel
EMA (1) ER positive, HER2-negative, PIK3CA amplification Invasive Breast Carcinoma Capivasertib, Fulvestrant
HSE (1) HER2-negative, PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab
HSE (1) HER2-negative, PD-L1 (CPS) >= 10 Adenocarcinoma of the Gastroesophageal Junction Fluorouracil, Oxaliplatin, Pembrolizumab
HSE (1) HER2-negative Invasive Breast Carcinoma Bevacizumab, Paclitaxel
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (2) HSE (1) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Exemestane
EMA (1) FDA (2) HSE (1) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Exemestane
HPRA (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole
HPRA (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole
HPRA (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Datopotamab deruxtecan
FDA (2) HER2-negative, PR positive Non-Small Cell Lung Cancer Datopotamab deruxtecan
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Datopotamab deruxtecan
EMA (1) FDA (2) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Imlunestrant
FDA (2) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (2) HER2-negative, PD-L1 (TAP) >= 1% Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
FDA (2) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Tislelizumab
FDA (2) HER2-negative, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Tislelizumab
EMA (1) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Abemaciclib, Camizestrant
EMA (1) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Camizestrant, Palbociclib
EMA (1) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Camizestrant, Ribociclib
EMA (1) HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Stomach Adenocarcinoma Capecitabine, Nivolumab, Oxaliplatin
EMA (1) HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Nivolumab, Oxaliplatin
EMA (1) HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Esophageal Adenocarcinoma Capecitabine, Nivolumab, Oxaliplatin
EMA (1) HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Stomach Adenocarcinoma Fluorouracil, Nivolumab, Oxaliplatin
FDA (2) ER positive, ESR1 activating variants, HER2-negative Invasive Breast Carcinoma Vepdegestrant
FDA (2) ER negative, HER2-negative, PD-L1 (CPS) >= 10, PR negative Invasive Breast Carcinoma Pembrolizumab, Sacituzumab govitecan